JPMorgan analyst Tessa Romero raised the firm’s price target on Cytokinetics (CYTK) to $97 from $92 and keeps an Overweight rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics announces new data related to Myqorzo at ESC Heart Failure 2026
- Cytokinetics price target raised to $140 from $136 at H.C. Wainwright
- Cytokinetics Raises $760 Million in Stock Offering
- Cytokinetics price target raised to $105 from $95 at Wells Fargo
- Cytokinetics 9.8M share Secondary priced at $71.00